This review assessed the effectiveness of anti-arrhythmic medications in reducing post-operative atrial tachyarrhythmia (AT) in general thoracic surgery. The authors concluded that calcium-channel blockers and beta-blockers both reduce post-operative AT, but evidence does not support the use of digitalis. This was generally a well-conducted review and the authors' conclusions are likely to be robust.
randomised to treatment groups. Any discrepancies were resolved through discussion among all reviewers. The authors of all selected studies were contacted for details of missing information. Unspecific reports of 'no major complications' were counted as missing data rather than zero events.
Methods of synthesis
How were the studies combined?
The studies were grouped according to the class of medication and combined using a fixed-effect meta-analysis, with weighting by the inverse of the variance. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Risk differences were also calculated and used to estimate the number of events averted or induced per 100 procedures, with 95% CI.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the chi-squared statistic.
Results of the review
Eleven RCTs (n=1,294) were included.
The quality scores ranged from 2 to 5. No statistically significant heterogeneity was found.
Calcium-channel blockers (4 RCTs, n=618) significantly reduced the risk of AT compared with placebo (RR 0.50, 95% CI: 0.34, 0.73). For every 100 patients treated, 11 episodes of AT were averted (95% CI: -17, -5). Calcium-channel blockers carried a slightly greater risk of adult respiratory distress syndrome (ARDS) than placebo, but this difference was not statistically significant (RR 1.31, 95% CI: 0.46, 3.72).
Beta-blockers (2 RCTs, n=129) significantly reduced the risk of AT compared with placebo (RR 0.40, 95% CI: 0.17, 0.95). For every 100 patients treated, 14 episodes of AT were averted (95% CI: -26, -2). Beta-blockers increased the risk of pulmonary oedema, although this was not statistically significant (RR 2.15, 95% CI: 0.74, 6.23).
Magnesium (1 RCT, n=194) significantly reduced the risk of AT compared with placebo (RR 0.40, 95% CI: 0.21, 0.78). For every 100 patients treated, 16 episodes of AT were averted (95% CI: -27, -5). No information on severe pulmonary complications with magnesium was reported.
Digitalis (3 RCTs, n=285) significantly increased the risk of AT compared with placebo (RR 1.51, 95% CI: 1.00, 2.28). No data on severe pulmonary complications with digitalis were reported.
The one RCT (n=30) of flecainide found no statistically significant difference between flecainide and placebo for AT (RR 0.16, 95% CI: 0.01, 2.89). No severe pulmonary complication events were reported
The one RCT (n=62) of amiodarone found no statistically significant difference between amiodarone and placebo for AT (RR 0.14, 95% CI: 0.02, 1.10). There was a greater risk of ARDS in the amiodarone group than the placebo group, but this difference was not statistically significant (RR 7.00, 95% CI: 0.38, 130.26).
Further analyses of the outcomes hypotension, bradycardia, myocardial ischaemia and mortality were presented.
